All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC0339 | Human anti-EBV Determinant Variant T cell receptor ((CF34)-2), pCDTCR1 | EBV | CF34 | Human | TLRGRAYGL | HLA-B*08:01 | Lentiviral vector | |
TCR-YC0340 | Human anti-EBV Determinant Variant T cell receptor ((CF34)-3), pCDTCR1 | EBV | CF34 | Human | YLRGRAYGL | HLA-B*08:01 | Lentiviral vector | |
TCR-YC0341 | Human anti-EBV Determinant Variant T cell receptor ((LC13)-1), pCDTCR1 | EBV | LC13 | Human | FLRGRAFGL | HLA-B*08:01 | Lentiviral vector | |
TCR-YC0342 | Human anti-EBV Determinant Variant T cell receptor ((LC13)-2), pCDTCR1 | EBV | LC13 | Human | FLRGRAYVL | HLA-B*08:01 | Lentiviral vector | |
TCR-YC0343 | Human anti-EBV Determinant Variant T cell receptor ((LC13)-3), pCDTCR1 | EBV | LC13 | Human | FLRGRFYGL | HLA-B*08:01 | Lentiviral vector | |
TCR-YC0344 | Human anti-EBV Determinant Variant T cell receptor ((LC13)-4), pCDTCR1 | EBV | LC13 | Human | TLRGRAYGL | HLA-B*08:01 | Lentiviral vector | |
TCR-YC0345 | Human anti-EBV Determinant Variant T cell receptor ((LC13)-5), pCDTCR1 | EBV | LC13 | Human | YLRGRAYGL | HLA-B*08:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION